AXL and cancer: Next, we evaluated the cell binding potential of sdAbs to AXL+ cancer cells (human HCT-116, murine CT26) using flow cytometry and sdAb affinity was determined using surface plasmon resonance (Figure 1C, Figure S1A,B).